DTC clock ticking
Executive Summary
Drug sponsors must notify FDA by Nov. 26 if they intend to submit DTC television ads to the agency for pre-broadcast review in fiscal 2008. Such a notification constitutes a legally binding commitment to pay a review fee, which will be calculated based on the number of ads to be reviewed (1"The Pink Sheet" Oct. 1, 2007, p. 4). The DTC user fee program, authorized by the FDA Amendments Act, will fund about 27 additional staff, enabling more rapid ad review. Guidance is forthcoming on contents, format and procedures for submitting DTC packages for review, the Oct. 25 Federal Register states...
You may also be interested in...
FDA Begins Reviewing DTC Ads As User Fee Program Faces Pay Or Die Deadline
Industry already has submitted 12 direct-to-consumer television ads to FDA for pre-review through the new DTC user fee program
DTC Fines May Be More Useful To Advertising Opponents Than An FDA Ban
Opponents of direct-to-consumer television ads will be better off with FDA having authority to fine companies for false and misleading television ads than they would have been if the agency was given the power to simply ban such ads, according to Scott Lassman, former Senior Assistant General Counsel at Pharmaceutical Research and Manufacturers of America
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.